{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:49:07Z","timestamp":1773110947006,"version":"3.50.1"},"reference-count":49,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0002_s_015_w2aab3b7b7b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Repeated intraperitoneal (IP) administration of paclitaxel (PTX) with concurrent systemic chemotherapy is clinically effective for the treatment of peritoneal metastases (PM) from gastric cancer. However, it is unclear how biochemical modifications may affect the pharmacokinetics and bioavailability of IP administered PTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0002_s_016_w2aab3b7b7b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a xenograft PM model using human gastric cancer cells, MKN45, fluorescein-conjugated PTX (OG-PTX) was given IP and the intra-tumor distribution of PTX examined with fluorescein microscopy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0002_s_017_w2aab3b7b7b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After IP injection, PTX was seen to directly infiltrate up to several hundred micrometers from the surface of the PM. Co-injection with 5\u2006% non-animal stabilized hyaluronic acid increased PTX infiltration and suppressed the development of PM more efficiently than PTX alone. PTX solubilized with amphiphilic polymer composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) and n-butyl methacrylate (BMA) efficiently formed a micellar formation 50\u2013100 nm in diameter. IP injection of the nanomicellar PTX (PTX-30W) also showed significantly enhanced tumor infiltration and further inhibition of the growth of PM compared with PTX solubilized with Cremophor\u2013ethanol (PTX-Cre). Finally, IP administration of NK105, another nanomicellar PTX, inhibited the growth of subcutaneous tumors as well as PM, compared with conventional PTX-Cre in the same murine model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0002_s_018_w2aab3b7b7b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PTX administered IP directly infiltrates PM and are thus a useful strategy for the treatment of PM. Drug modification with nanotechnology may further enhance penetration of PM resulting in improved clinical efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0002","type":"journal-article","created":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T06:02:03Z","timestamp":1491026523000},"page":"95-102","source":"Crossref","is-referenced-by-count":12,"title":["Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model"],"prefix":"10.1515","volume":"2","author":[{"given":"Joji","family":"Kitayama","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery , Jichi Medical University , Shimotsuke , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Ishigami","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology , Jichi Medical University , Shimotsuke , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Soma","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyo","family":"Miyato","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery , Jichi Medical University , Shimotsuke , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Kamei","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Kawarai","family":"Lefor","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery , Jichi Medical University , Shimotsuke , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery , Jichi Medical University , Shimotsuke , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"2025120909204644845_j_pp-2017-0002_ref_001_w2aab3b7b7b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH, Peritoneal-plasma barrier. Cancer Treat Res 1996;82:53\u201363.","DOI":"10.1007\/978-1-4613-1247-5_4"},{"key":"2025120909204644845_j_pp-2017-0002_ref_002_w2aab3b7b7b1b6b1ab2b1b2Aa","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT, Jr., Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1\u201311."},{"key":"2025120909204644845_j_pp-2017-0002_ref_003_w2aab3b7b7b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D, Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112\u201322.","DOI":"10.1634\/theoncologist.10-2-112"},{"key":"2025120909204644845_j_pp-2017-0002_ref_004_w2aab3b7b7b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284\u201392.","DOI":"10.1200\/JCO.2004.10.012"},{"key":"2025120909204644845_j_pp-2017-0002_ref_005_w2aab3b7b7b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH, Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011\u20139.","DOI":"10.1200\/JCO.2006.07.1142"},{"key":"2025120909204644845_j_pp-2017-0002_ref_006_w2aab3b7b7b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Kitayama J. Intraperitoneal chemotherapy against peritoneal carcinomatosis: Current status and future perspective. Surg Oncol 2014;23:99\u2013106.","DOI":"10.1016\/j.suronc.2014.03.004"},{"key":"2025120909204644845_j_pp-2017-0002_ref_007_w2aab3b7b7b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 2016;42:1123\u201331.","DOI":"10.1016\/j.ejso.2016.03.016"},{"key":"2025120909204644845_j_pp-2017-0002_ref_008_w2aab3b7b7b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Munoz-Casares FC, Medina-Fernandez FJ, Arjona-Sanchez A, Casado-Adam A, Sanchez-Hidalgo JM, Rubio MJ, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center. European J Surg Oncol 2016;42:224\u201333.","DOI":"10.1016\/j.ejso.2015.11.006"},{"key":"2025120909204644845_j_pp-2017-0002_ref_009_w2aab3b7b7b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Markman M, Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol 2003;4:277\u201383.","DOI":"10.1016\/S1470-2045(03)01074-X"},{"key":"2025120909204644845_j_pp-2017-0002_ref_010_w2aab3b7b7b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994;34:465\u201371.","DOI":"10.1007\/BF00685656"},{"key":"2025120909204644845_j_pp-2017-0002_ref_011_w2aab3b7b7b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010;21:67\u201370.","DOI":"10.1093\/annonc\/mdp260"},{"key":"2025120909204644845_j_pp-2017-0002_ref_012_w2aab3b7b7b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013;71:1265\u201372.","DOI":"10.1007\/s00280-013-2122-0"},{"key":"2025120909204644845_j_pp-2017-0002_ref_013_w2aab3b7b7b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol 2012;105:38\u201342.","DOI":"10.1002\/jso.22057"},{"key":"2025120909204644845_j_pp-2017-0002_ref_014_w2aab3b7b7b1b6b1ab2b1c14Aa","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T, A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 2013;119:3354\u20138."},{"key":"2025120909204644845_j_pp-2017-0002_ref_015_w2aab3b7b7b1b6b1ab2b1c15Aa","unstructured":"Hosie K, Gilbert JA, Kerr D, Brown CB, Peers EM, Fluid dynamics in man of an intraperitoneal drug delivery solution: 4\u2006% icodextrin. Drug Deliv 2001;8:9\u201312."},{"key":"2025120909204644845_j_pp-2017-0002_ref_016_w2aab3b7b7b1b6b1ab2b1c16Aa","unstructured":"Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH, Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 2003;52:405\u201310."},{"key":"2025120909204644845_j_pp-2017-0002_ref_017_w2aab3b7b7b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Luo Y, Kirker KR, Prestwich GD, Cross-linked hyaluronic acid hydrogel films: New biomaterials for drug delivery. J Control Release 2000;69:169\u201384.","DOI":"10.1016\/S0168-3659(00)00300-X"},{"key":"2025120909204644845_j_pp-2017-0002_ref_018_w2aab3b7b7b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Wang Y, Gong C, Yang L, Wu Q, Shi S, Shi H, et al. 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer 2010;10:402.","DOI":"10.1186\/1471-2407-10-402"},{"key":"2025120909204644845_j_pp-2017-0002_ref_019_w2aab3b7b7b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Yu J, Lee HJ, Hur K, Kwak MK, Han TS, Kim WH, et al. The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model. Invest New Drugs 2012;30:1\u20137.","DOI":"10.1007\/s10637-010-9499-y"},{"key":"2025120909204644845_j_pp-2017-0002_ref_020_w2aab3b7b7b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Bajaj G, Kim MR, Mohammed SI, Yeo Y, Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release 2012;158:386\u201392.","DOI":"10.1016\/j.jconrel.2011.12.001"},{"key":"2025120909204644845_j_pp-2017-0002_ref_021_w2aab3b7b7b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"sEmoto S, Yamaguchi H, Kamei T, Ishigami H, Suhara T, Suzuki Y, et al. Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg Today 2014;44(5):919\u201326.","DOI":"10.1007\/s00595-013-0674-6"},{"key":"2025120909204644845_j_pp-2017-0002_ref_022_w2aab3b7b7b1b6b1ab2b1c22Aa","unstructured":"Matsumura Y, Maeda H, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387\u201392."},{"key":"2025120909204644845_j_pp-2017-0002_ref_023_w2aab3b7b7b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271\u201384.","DOI":"10.1016\/S0168-3659(99)00248-5"},{"key":"2025120909204644845_j_pp-2017-0002_ref_024_w2aab3b7b7b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A, Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine 2016;12:81\u2013103.","DOI":"10.1016\/j.nano.2015.08.006"},{"key":"2025120909204644845_j_pp-2017-0002_ref_025_w2aab3b7b7b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloyloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci 2011;102:200\u201305.","DOI":"10.1111\/j.1349-7006.2010.01747.x"},{"key":"2025120909204644845_j_pp-2017-0002_ref_026_w2aab3b7b7b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Soma D, Kitayama J, Konno T, Ishihara K, Yamada J, Kamei T, et al. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci 2009;100:1979\u201385.","DOI":"10.1111\/j.1349-7006.2009.01265.x"},{"key":"2025120909204644845_j_pp-2017-0002_ref_027_w2aab3b7b7b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Sako A, Kitayama J, Koyama H, Ueno H, Uchida H, Hamada H, et al. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res 2004;64:3624\u20138.","DOI":"10.1158\/0008-5472.CAN-04-0304"},{"key":"2025120909204644845_j_pp-2017-0002_ref_028_w2aab3b7b7b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Konno T, Watanabe J, Ishihara K, Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A 2003;65:209\u201314.","DOI":"10.1002\/jbm.a.10481"},{"key":"2025120909204644845_j_pp-2017-0002_ref_029_w2aab3b7b7b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Yamada J, Kitayama J, Tsuno NH, Yamashita H, Miyato H, Soma D, et al. Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle\u2013a new strategy against peritoneal dissemination of gastric cancer. Cancer Lett 2008;272:307\u201315.","DOI":"10.1016\/j.canlet.2008.07.024"},{"key":"2025120909204644845_j_pp-2017-0002_ref_030_w2aab3b7b7b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Andre P, Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA \u2013 Q-Medical, Sweden) in European countries: A retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol 2004;18:422\u20135.","DOI":"10.1111\/j.1468-3083.2004.00934.x"},{"key":"2025120909204644845_j_pp-2017-0002_ref_031_w2aab3b7b7b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Friedman PM, Mafong EA, Kauvar AN, Geronemus RG, Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002;28:491\u20134.","DOI":"10.1097\/00042728-200206000-00010"},{"key":"2025120909204644845_j_pp-2017-0002_ref_032_w2aab3b7b7b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Emoto S, Yamaguchi H, Kishikawa J, Yamashita H, Ishigami H, Kitayama J, Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. Cancer Sci 2012;103:1304\u201310.","DOI":"10.1111\/j.1349-7006.2012.02274.x"},{"key":"2025120909204644845_j_pp-2017-0002_ref_033_w2aab3b7b7b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005;92:1240\u20136.","DOI":"10.1038\/sj.bjc.6602479"},{"key":"2025120909204644845_j_pp-2017-0002_ref_034_w2aab3b7b7b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Mukai H, Kato K, Esaki T, Ohsumi S, Hozomi Y, Matsubara N, et al. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. Invest New Drugs 2016;34:750\u20139.","DOI":"10.1007\/s10637-016-0381-4"},{"key":"2025120909204644845_j_pp-2017-0002_ref_035_w2aab3b7b7b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 2011;67:1265\u201372.","DOI":"10.1007\/s00280-010-1422-x"},{"key":"2025120909204644845_j_pp-2017-0002_ref_036_w2aab3b7b7b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Armstrong DK, Fleming GF, Markman M, Bailey HH, A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2006;103:391\u20136.","DOI":"10.1016\/j.ygyno.2006.02.029"},{"key":"2025120909204644845_j_pp-2017-0002_ref_037_w2aab3b7b7b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol 2014;21:539\u2013546.","DOI":"10.1245\/s10434-013-3208-y"},{"key":"2025120909204644845_j_pp-2017-0002_ref_038_w2aab3b7b7b1b6b1ab2b1c38Aa","unstructured":"Los G, Mutsaers PH, Van Der Vijgh WJ, Baldew GS, De Graaf PW, McVie JG, Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380\u20134."},{"key":"2025120909204644845_j_pp-2017-0002_ref_039_w2aab3b7b7b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL, Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol 1985;248:H26\u201332.","DOI":"10.1152\/ajpheart.1985.248.1.H26"},{"key":"2025120909204644845_j_pp-2017-0002_ref_040_w2aab3b7b7b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"El-Kareh AW, Secomb TW, A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 2004;6:117\u201327.","DOI":"10.1593\/neo.03205"},{"key":"2025120909204644845_j_pp-2017-0002_ref_041_w2aab3b7b7b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Yokogawa K, Jin M, Furui N, Yamazaki M, Yoshihara H, Nomura M, et al. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles. J Pharm Pharmacol 2004;56:629\u201334.","DOI":"10.1211\/0022357023303"},{"key":"2025120909204644845_j_pp-2017-0002_ref_042_w2aab3b7b7b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"De Smet L, Colin P, Ceelen W, Bracke M, Van Bocxlaer J, Remon JP, et al. Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment. Pharm Res 2012;29:2398\u2013406.","DOI":"10.1007\/s11095-012-0765-x"},{"key":"2025120909204644845_j_pp-2017-0002_ref_043_w2aab3b7b7b1b6b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"Lim Soo P, Cho J, Grant J, Ho E, Piquette-Miller M, Allen C, Drug release mechanism of paclitaxel from a chitosan-lipid implant system: Effect of swelling, degradation and morphology. Eur J Pharm Biopharm 2008;69:149\u201357.","DOI":"10.1016\/j.ejpb.2007.11.003"},{"key":"2025120909204644845_j_pp-2017-0002_ref_044_w2aab3b7b7b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Walkey CD, Chan WC, Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev 2012;41:2780\u201399.","DOI":"10.1039\/C1CS15233E"},{"key":"2025120909204644845_j_pp-2017-0002_ref_045_w2aab3b7b7b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Dakwar GR, Braeckmans K, Demeester J, Ceelen W, De Smedt SC, Remaut K, Disregarded effect of biological fluids in sirna delivery: human ascites fluid severely restricts cellular uptake of nanoparticles. ACS Appl Mater Interfaces 2015;7:24322\u20139.","DOI":"10.1021\/acsami.5b08805"},{"key":"2025120909204644845_j_pp-2017-0002_ref_046_w2aab3b7b7b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Simon-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore AM, et al. Paclitaxel-loaded polymersomes for enhanced intraperitoneal chemotherapy. Mol Cancer Ther 2016;15:670\u20139.","DOI":"10.1158\/1535-7163.MCT-15-0713-T"},{"key":"2025120909204644845_j_pp-2017-0002_ref_047_w2aab3b7b7b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Minchinton AI, Tannock IF, Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583\u201392.","DOI":"10.1038\/nrc1893"},{"key":"2025120909204644845_j_pp-2017-0002_ref_048_w2aab3b7b7b1b6b1ab2b1c48Aa","doi-asserted-by":"crossref","unstructured":"Ma P, Mumper RJ, Paclitaxel nano-delivery systems: A comprehensive review. J Nanomed Nanotechnol 2013;4:1000164.","DOI":"10.4172\/2157-7439.1000164"},{"key":"2025120909204644845_j_pp-2017-0002_ref_049_w2aab3b7b7b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"Dakwar GR, Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K, Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - mission possible?. Adv Drug Deliv Rev 2017;108:13\u201324.","DOI":"10.1016\/j.addr.2016.07.001"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/2\/article-p95.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0002\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:37:55Z","timestamp":1765276675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0002\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,6]]},"published-print":{"date-parts":[[2017,6,5]]}},"alternative-id":["10.1515\/pp-2017-0002"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0002","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}